Pharmaceutical Research

, Volume 29, Issue 6, pp 1637–1649 | Cite as

Multi-Compartmental Nanoparticles-in-Emulsion Formulation for Macrophage-Specific Anti-Inflammatory Gene Delivery

Research Paper

ABSTRACT

Purpose

To develop a safe and effective non-viral vector for gene delivery and transfection in macrophages for potential anti-inflammatory therapy.

Methods

Solid nanoparticles-in-emulsion (NiE) multi-compartmental delivery system was designed using plasmid DNA-encapsulated type B gelatin nanoparticles suspended in the inner aqueous phase of safflower oil-containing water-in-oil-in-water (W/O/W) multiple emulsion. Control and NiE formulations were evaluated for DNA delivery and transfection efficiency in J774A.1 adherent murine macrophages.

Results

Using green fluorescent protein (GFP) and murine interleukin-10 (mIL-10) expressing plasmid DNA constructs, the NiE formulation was found superior in enhancing intracellular delivery and gene transfection efficiency in cells. Anti-inflammatory effects of transfected mIL-10 were examined by suppression of tumor necrosis factor-alpha (TNFα) and interleukin 1-beta (IL-1β) production in lipopolysaccharide (LPS)-stimulated cells.

Conclusions

Overall, the results were very encouraging towards development of a macrophage-specific NiE-based multi-compartmental gene delivery strategy that can potentially affect a number of acute and chronic inflammatory diseases.

KEY WORDS

anti-inflammatory therapy macrophage-targeted mIL-10 transfection nanoparticles-in-emulsion non-viral gene delivery 

Notes

ACKNOWLEDGMENTS & DISCLOSURES

This study was supported by a grant (R01-DK080477) from the National Institute of Diabetes, Digestive Diseases, and Kidney Diseases of the National Institutes of Health. We deeply appreciate the assistance of Ms. Jing Xu with the transmission electron microscopy analysis that was performed at the Electron Microscopy Center of Northeastern University.

REFERENCES

  1. 1.
    Fujiwara N, Kobayashi K. Macrophages in inflammation. Curr Drug Targets Inflamm Allergy. 2005;4:281–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Mohan H. Textbook of pathology. New Delhi: Jaypee Bros; 2005.Google Scholar
  3. 3.
    Glaros T, Larsen M, Li L. Macrophages and fibroblasts during inflammation, tissue damage and organ injury. Front Biosci. 2009;14:3988–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Mosser DM. The many faces of macrophage activation. J Leukoc Biol. 2003;73:209–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453–61.PubMedCrossRefGoogle Scholar
  6. 6.
    Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature. 1988;334:260–2.PubMedCrossRefGoogle Scholar
  7. 7.
    Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Docke WD. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest. 1998;101:783–94.PubMedCrossRefGoogle Scholar
  8. 8.
    Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infection. J Immunol. 2008;180:5771–7.PubMedGoogle Scholar
  9. 9.
    Chernajovsky Y, Gould DJ, Podhajcer OL. Gene therapy for autoimmune diseases: quo vadis? Nat Rev Immunol. 2004;4:800–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet. 2005;6:299–310.PubMedCrossRefGoogle Scholar
  11. 11.
    Brown MD, Schatzlein AG, Uchegbu IF. Gene delivery with synthetic (non viral) carriers. Int J Pharm. 2001;229:1–21.PubMedCrossRefGoogle Scholar
  12. 12.
    Bhavsar MD, Amiji MM. Polymeric nano- and microparticle technologies for oral gene delivery. Expert Opin Drug Deliv. 2007;4:197–213.PubMedCrossRefGoogle Scholar
  13. 13.
    Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials. 2008;29:3477–96.PubMedCrossRefGoogle Scholar
  14. 14.
    Bhavsar MD, Amiji MM. Development of novel biodegradable polymeric nanoparticles-in-microsphere formulation for local plasmid DNA delivery in the gastrointestinal tract. AAPS PharmSciTech. 2008;9:288–94.PubMedCrossRefGoogle Scholar
  15. 15.
    Bhavsar MD, Amiji MM. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther. 2008;15:1200–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Kaul G, Amiji M. Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm Res. 2005;22:951–61.PubMedCrossRefGoogle Scholar
  17. 17.
    Kaul G, Amiji M. Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm Res. 2002;19:1061–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Kommareddy S, Amiji M. Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Ther. 2007;14:488–98.PubMedCrossRefGoogle Scholar
  19. 19.
    Kommareddy S, Amiji M. Preparation and evaluation of thiol-modified gelatin nanoparticles for intracellular DNA delivery in response to glutathione. Bioconjug Chem. 2005;16:1423–32.PubMedCrossRefGoogle Scholar
  20. 20.
    Kriegel C, Amiji M. Oral TNF-alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J Control Release. 2011;150:77–86.Google Scholar
  21. 21.
    Magadala P, Amiji M. Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells. AAPS J. 2008;10:565–76.PubMedCrossRefGoogle Scholar
  22. 22.
    Xu J, Ganesh S, Amiji M. Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery. Int J Pharm. 2011. doi:10.1016/j.ijpharm.2011.05.036
  23. 23.
    Shahiwala A, Amiji MM. Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice. J Drug Target. 2008;16:302–10.PubMedCrossRefGoogle Scholar
  24. 24.
    Deshpande D, Devalapally H, Amiji M. Enhancement in anti-proliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles. Pharm Res. 2008;25:1936–47.PubMedCrossRefGoogle Scholar
  25. 25.
    Kommareddy S, Amiji M. Poly(ethylene glycol)-modified thiolated gelatin nanoparticles for glutathione-responsive intracellular DNA delivery. Nanomedicine. 2007;3:32–42.PubMedCrossRefGoogle Scholar
  26. 26.
    Kommareddy S, Amiji MM. Protein nanospheres for gene delivery: preparation and in vitro transfection studies with gelatin nanoparticles. In: Friedmann T, Rossi J, editors. Gene Transfer: Delivery and Expression of DNA and RNA – A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 2007, Chapter 52, pp 527--540.Google Scholar
  27. 27.
    Kommareddy S, Tiwari S, Amiji MM. Long-circulating nanovectors for tumor-specific gene delivery. Tech Canc Res Treat. 2005;4(6):615–625.Google Scholar
  28. 28.
    Bhavsar MD, Amiji MM. Gastrointestinal distribution and in vivo gene transfection studies with nanoparticles-in-microsphere oral system (NiMOS). J Contr Release. 2007;119:339–48.CrossRefGoogle Scholar
  29. 29.
    Bhavsar MD, Tiwari SB, Amiji MM. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Contr Release. 2006;110:422–30.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences, School of PharmacyNortheastern UniversityBostonUSA

Personalised recommendations